-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 ---- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings ---- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 ...